Chicago—Phase 3 clinical trial results reported at the annual meeting of the American Society of Clinical Oncology (ASCO) are expected to spark changes in the management of patients with chronic lymphocytic leukemia (CLL) and individuals with cancer of the prostate, breast, or ovaries.
Adding adjuvant chemotherapy to radiation in patients with low-grade glioma improved overall survival by 5.5 years, said Jan Buckner, MD, chair of oncology at Mayo Clinic, Rochester, Minnesota, who presented results from the Radiation Therapy Oncology Group (RTOG) 9802 trial.
O’Rourke K. New Practice-Changing Study Findings Presented at ASCO. JAMA. 2014;312(3):218-219. doi:10.1001/jama.2014.7708